Tag Archives: University of Rochester Medical Center

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Copper Disrupts Brain Amyloid-β Production and Clearance? (NHS Choices / PNAS)

Summary This NHS Choices “Behind the Headlines” critical appraisal of recent research in the news is about a laboratory study carried out on mice and human brain cells, investigating whether copper may reduce the capacity of the brain to get … Continue reading

Posted in Animal Studies, For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Proposed for Next Newsletter, Quick Insights, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment